MX2019008643A - Uso de serlopitant como antagonistas del receptor nk-1 en prurito. - Google Patents

Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Info

Publication number
MX2019008643A
MX2019008643A MX2019008643A MX2019008643A MX2019008643A MX 2019008643 A MX2019008643 A MX 2019008643A MX 2019008643 A MX2019008643 A MX 2019008643A MX 2019008643 A MX2019008643 A MX 2019008643A MX 2019008643 A MX2019008643 A MX 2019008643A
Authority
MX
Mexico
Prior art keywords
serlopitant
pruritus
receptor antagonist
receptor antagonists
additional
Prior art date
Application number
MX2019008643A
Other languages
English (en)
Inventor
W Larrick James
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
Original Assignee
Menlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc filed Critical Menlo Therapeutics Inc
Publication of MX2019008643A publication Critical patent/MX2019008643A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para tratar el prurito con antagonistas del receptor NK-1 tales como serlopitant. La invención se refiere, además, a composiciones farmacéuticas que comprenden antagonistas del receptor NK-1 tales como serlopitant. Además, la invención abarca el tratamiento de una condición asociada con el prurito con serlopitant y un agente antiprurítico adicional, y el uso de serlopitant como un auxiliar del sueño, opcionalmente en combinación con un agente adicional auxiliar del sueño.
MX2019008643A 2013-06-24 2015-12-18 Uso de serlopitant como antagonistas del receptor nk-1 en prurito. MX2019008643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus

Publications (1)

Publication Number Publication Date
MX2019008643A true MX2019008643A (es) 2019-09-10

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017763A MX366728B (es) 2013-06-24 2014-06-24 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.
MX2019008643A MX2019008643A (es) 2013-06-24 2015-12-18 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015017763A MX366728B (es) 2013-06-24 2014-06-24 Uso de serlopitant como antagonistas del receptor nk-1 en prurito.

Country Status (13)

Country Link
EP (1) EP3013336A1 (es)
JP (2) JP2016523260A (es)
KR (1) KR20160023692A (es)
CN (1) CN105473138A (es)
AU (2) AU2014302694B2 (es)
BR (1) BR112015031724A2 (es)
CA (1) CA2915474A1 (es)
HK (1) HK1223820A1 (es)
IL (1) IL243189A0 (es)
MX (2) MX366728B (es)
PH (2) PH12015502777A1 (es)
RU (1) RU2666219C2 (es)
WO (1) WO2014209962A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
KR102424837B1 (ko) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 아프레피탄트의 에멀젼 제형
KR20170122777A (ko) * 2015-03-04 2017-11-06 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US20190216779A1 (en) * 2016-06-29 2019-07-18 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
BR112020008714A2 (pt) * 2017-11-01 2020-11-03 National University Of Singapore uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN115015440A (zh) * 2022-07-08 2022-09-06 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
AU2006269383A1 (en) 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
EP1937264B1 (en) 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
JP2010502703A (ja) * 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
US20090270477A1 (en) 2006-11-02 2009-10-29 Kuethe Jeffrey T Polymorphs of a hydroisoindoline tachykinin receptor antagonist
AU2008233232A1 (en) 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Also Published As

Publication number Publication date
PH12020500255A1 (en) 2021-02-22
RU2015154037A (ru) 2017-07-28
JP2019142960A (ja) 2019-08-29
BR112015031724A2 (pt) 2017-07-25
PH12015502777A1 (en) 2016-03-21
WO2014209962A1 (en) 2014-12-31
AU2014302694A1 (en) 2016-01-07
RU2666219C2 (ru) 2018-09-06
CA2915474A1 (en) 2014-12-31
EP3013336A1 (en) 2016-05-04
MX2015017763A (es) 2016-06-21
HK1223820A1 (zh) 2017-08-11
CN105473138A (zh) 2016-04-06
IL243189A0 (en) 2016-02-29
AU2020200259A1 (en) 2020-02-06
KR20160023692A (ko) 2016-03-03
AU2014302694B2 (en) 2019-10-17
MX366728B (es) 2019-07-22
JP2016523260A (ja) 2016-08-08

Similar Documents

Publication Publication Date Title
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
PH12016500642B1 (en) Selective substituted quinoline compounds
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
MX2015002292A (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
ZA201506131B (en) Kv1.3 antagonists and methods of use
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
ME03086B (me) Antagonisтi kv1.3 i postupci za upotrebu
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.